Atorvastatin in Severity-stratified Pulmonary Sarcoidosis: A Phase II Randomized Controlled Trial

Am J Respir Crit Care Med. 2024 Dec 19. doi: 10.1164/rccm.202403-0526RL. Online ahead of print.

¹ NIH/NHLBI, CCMPB, Bethesda, Maryland, United States; [email protected].
² NIH, CCMPB, Bethesda, United States.
³ National Heart Lung and Blood Institute, Office of Biostatistics Research, Bethesda, Maryland, United States.
⁴ National Institutes of Health, Office of Biostatistics Research, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States.
⁵ NHLBI, National Institutes of Health, CCMPB, Bethesda, Maryland, United States.
⁶ National Institutes of Health, National Heart Lung and Blood Institute/CCMPB, Bethesda, Maryland, United States.
⁷ NIH/NHLBI, CCMPB, Bethesda, Maryland, United States.
⁸ Moffitt Cancer Center, Tampa, Florida, United States.
⁹ University of Texas Medical School at Houston Department of Internal Medicine, Houston, Texas, United States.
¹⁰ NIH, National Heart, Lung, and Blood Institute, Bethesda, Maryland, United States.

No abstract available

Keywords: Disease Progression; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunomodulation; Inflammation; Respiratory Function.